PharmaCyte Biotech (PMCB)
NASDAQ:PMCB
Holding PMCB?
Track your performance easily

PharmaCyte Biotech (PMCB) Income Statement

215 Followers

PharmaCyte Biotech Income Statement

Last quarter (Q ), PharmaCyte Biotech's total revenue was $―, a decrease of ― from the same quarter last year. In Q, PharmaCyte Biotech's net income was $-5.86M. See PharmaCyte Biotech’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Apr 24Apr 23Apr 22Apr 21Apr 20
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.52M$ 8.52M$ 6.46M$ 4.39M$ 3.62M$ 3.83M
Operating Income
$ -8.52M$ -8.52M$ -6.46M$ -4.39M$ -3.62M$ -3.83M
Net Non Operating Interest Income Expense
$ 3.40M$ 3.40M$ 1.94M$ 157.14K$ 72.93K$ -453.00
Other Income Expense
$ 3.38M$ 3.38M$ -202.00K$ 4.28K$ 1.19K$ -40.00
Pretax Income
$ -6.50M$ -6.50M$ -4.32M$ -4.24M$ -3.55M$ -3.83M
Tax Provision
--$ -906.36K$ -890.22K$ -1.89K-
Earnings From Equity Interest Net Of Tax
--$ 5.88K---
Net Income Common Stockholders
$ -17.24M$ -17.24M$ -4.32M$ -4.24M$ -3.55M$ -3.83M
Basic EPS
$ -1.80$ -1.80$ -0.22$ -0.27$ -2.45$ -4.23
Diluted EPS
$ -1.80$ -1.80$ -0.22$ -0.27$ -2.45$ -4.23
Basic Average Shares
$ 38.32M$ 9.58M$ 19.49M$ 15.52M$ 1.45M$ 904.26K
Diluted Average Shares
$ 38.32M$ 9.58M$ 19.49M$ 15.52M$ 1.45M$ 904.26K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 8.52M$ 8.52M$ 6.46M$ 4.39M$ 3.62M$ 3.83M
Net Income From Continuing And Discontinued Operation
$ 333.76K$ 333.76K$ -4.32M$ -4.24M$ -3.55M$ -3.83M
Normalized Income
$ -2.87M$ -2.87M$ -5.22M--$ -3.83M
Interest Expense
-----$ 453.00
EBIT
$ -915.65K$ 333.76K$ -4.32M$ -4.24M$ -3.62M$ -3.83M
EBITDA
$ -915.65K$ 333.76K$ -4.32M$ -4.24M$ -3.62M$ -3.83M
Currency in USD

PharmaCyte Biotech Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis